Table 1 Demographics and disease characteristics I
THERAPEUTIC ME INDICATION | PROPHYLACTIC ME INDICATION | ||||
|---|---|---|---|---|---|
NO IBLR or NP (DF-cohort) 87 patients/ 108 breasts | WITH IBLR/NP (D-cohort) 18 patients/ 18 breasts | p-VALUE | NO NP (DF-cohort) 29 patients/ 54 breasts | WITH NP (D-cohort) 1 patient/ 1 breast | |
Age (mean years, SD)PB | 50.3 ± 11.4 | 46.0 ± 17.1 | .067 | 41.0 ± 9.4 | 66.2 |
BMI (mean kg/m2, SD)PP | 25.56 ± 5.94 | 24.19 ± 3.58 | .644 | 25.53 ± 5.26 | NA |
Prior breast operationPB | 18 (16.7%) | 6 (33.3%) | .110 | 9 (16.7%) | 0 |
Neoadjuvant chemotherapy (NACT)PP | 24 (27.6%) | 4 (22.2%) | > .999 | ||
Radiotherapy(RT)PB | 26 (24.1%) | 4 (22.2%) | > .999 | ||
- Prior to ME | 1 (0.9%) | 1 (5.6%) | .266 | ||
- Post ME | 25 (23.1%) | 3 (16.7%) | .761 | ||
Breast cancer subtypePB | .931 | ||||
- Luminal A | 31 (30.7%) | 4 (25.0%) | |||
- Luminal B | 20 (19.8%) | 4 (25.0%) | |||
- HER2-enriched | 33 (32.7%) | 5 (31.2%) | |||
- Triple negative | 17 (16.8%) | 3 (18.8%) | |||